Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

How Consumerism, Technology, and Pandemic are Accelerating the Future


At a time when the healthcare industry is accelerating the adoption of telehealth and virtual care models in the wake of the pandemic, Healthcare Digital Transformation: How Consumerism, Technology, and Pandemic are Accelerating the Future (Taylor & Francis, August 2020) is an essential handbook and guide for digital health and digital transformation leaders in healthcare in response to the pandemic and changing consumer preferences.

The new book by Paddy Padmanabhan, CEO of Damo Consulting, and Edward Marx, Chief Digital Officer, The HCI Group, is a reference guide for healthcare executives and technology providers responsible for telehealth and digital front door solutions and for leaders involved in the ongoing digital transformation of the healthcare sector. It provides telehealth and digital transformation strategies for a post-pandemic era.

Based on the authors’ extensive experience as hands-on practitioners, Healthcare Digital Transformation provides actionable insights on developing enterprise digital roadmaps and implementing digital health solutions at every touchpoint in a consumer’s journey for a post-COVID-19 future. With strong backgrounds in healthcare technology, the authors provide practical insights and guidance on developing robust digital roadmaps, picking the right technology partners, and implementing enterprise digital transformation successfully using agile principles.

“The idea for the book came together as the result of the work that Ed and I did together while he was the CIO of Cleveland Clinic,” said Padmanabhan. “I am grateful to Ed for the partnership on this book. We spoke with over 150 healthcare and technology executives in writing this book. Their insights, especially with digital transformation, and their pandemic response have greatly informed the various themes we have explored in writing the book. This book provides insights on the future of healthcare in a post-COVID-19 era and healthcare’s digital transformation journey,” he adds.

“COVID-19 has forced us to rethink our options for accelerating healthcare digital transformation,” said Marx. “We need to embrace the digital health platforms in dealing with the disruption of the pandemic, find opportunities for innovation, and prepare for the post-pandemic era. My association with Paddy goes back to several years and I am once again pleased to work with him in writing this book,” he adds.

About the authors:

Paddy Padmanabhan is an award-winning business leader and entrepreneur with deep experience in healthcare technology markets. Paddy is the Founder and CEO of Damo Consulting Inc., a digital transformation and growth advisory firm focused on healthcare. He is also the author of the best-selling book The Big Unlock – Harnessing Data and Growing Digital Health Businesses in a Value-based Care Era (Archway Publishing, 2017). Paddy is the host of the highly subscribed The Big Unlock podcast on digital transformation in healthcare featuring C-level executives from the healthcare and technology sectors. He is widely published and has a by-lined column in CIO Magazine and other respected industry publications. Paddy is a graduate of the executive management program of the University of Chicago Booth School of Business, holds an MBA from Indian Institute of Management, and a B.S in Engineering from the Indian Institute of Technology.

Edward Marx serves as the Chief Digital Officer for Tech Mahindra / HCI Health & Life Sciences division. He has served as CIO in many progressive organizations that include Cleveland Clinic, New York City Health & Hospitals, Texas Health Resources, and University Hospitals of Cleveland. Edward began his distinguished military career starting as a combat medic and finishing as a combat engineer officer. He is the author of several books including the best-selling Voices of Innovation (2019), Scenes from an Early Morning Run (2019), Extraordinary Tales of a Rather Ordinary Man (2015). In his spare time Edward races for Team USA Duathlon and loves to hike and climb mountains with his wife Simran. Edward received his bachelor’s in psychology and master’s in design, merchandising and consumer sciences, all from Colorado State University.

About Damo Consulting Inc.

Damo Consulting provides digital transformation advisory services to enable healthcare organizations navigate the technology-enabled transition to telehealth and virtual care. We bring deep industry knowledge, market insights and technology skills to help develop and implement enterprise digital roadmaps. We work with healthcare IT and digital health firms to develop and execute market growth strategies.

For media enquiries, write to:

info@damoconsulting.net or Tess Woods | tess@tesswoodspr.com | 617-942-0336

The book is available on Amazon and here: https://thebigunlock.com/healthcare-digital-transformation-book-by-paddy-padmanabhan-and-edward-w-marx/

Share article on social media or email:

Total Spectrum Launches New ABA Therapy Learning Center in Brookfield, Wisconsin


Total Spectrum Launches New ABA Therapy Learning Center in Brookfield, Wisconsin

Total Spectrum Launches New ABA Therapy Learning Center in Brookfield, Wisconsin

Total Spectrum is excited to bring superior ABA Services the Greater Brookfield community.

Total Spectrum, a company of behavioral clinicians specializing in the care of children with Autism Spectrum Disorder (ASD) in Wisconsin, is delighted to announce the grand opening of their new ABA learning center in Brookfield, Wisconsin. With the opening of their newest center, Total Spectrum now proudly serves ten different locations across the Midwest. The staff of Total Spectrum extends a warm greeting to the Brookfield community and welcomes anyone who has an interest in joining our family to apply.

“Total Spectrum is excited to bring superior ABA Services the Greater Brookfield community. Our team of highly skilled Registered Behavior Technicians (RBT’s) and Board Certified Behavior Analysts (BCBAs) are dedicated to the success of our clients and families. As a company, we value the importance of ongoing staff training, clinical supervision, and regular communication with our families regarding their child’s treatment plan and goals,” said Brooke Marcellis, Clinical Director for the Brookfield Learning Center.

At Total Spectrum, ABA services are developed and supervised by Board Certified Behavior Analysts (BCBAs) who are licensed and experienced in the treatment of Autism Spectrum Disorders (ASD). After identifying each client’s areas of need, the BCBA develops a treatment and behavior plan tailored for them accordingly. These plans include objective and measurable goals while outlining both baseline and mastery criteria.

In each ABA learning center, therapists focus on improving social skills, coping and tolerance skills, family relationships, school readiness skills, vocational skills, independence as well as community participation.

Due to COVID-19 regulations, the new Brookfield center is currently offering social skills groups via Zoom until restrictions are lifted. For parents who are working and do not have additional time to join weekly zoom calls, Total Spectrum will also begin offering Saturday groups from 9 AM – 2 PM in August 2020.

About Total Spectrum

Total Spectrum’s mission is to help children with Autism Spectrum Disorder (ASD) reach their maximum potential. With over 30 years of healthcare background, our team knows what it takes to achieve success. Our staff believes that every child deserves individualized attention in order to achieve their maximum level of independence. Using Applied Behavior Analysis, our team can also help to reduce behavioral challenges and increase skills important for daily life. Serving multiple cities across the Midwest, our team strives to provide a comfortable and enjoyable environment for every child and their family. For more information about our services, please visit https://www.totalspectrumcare.com/

Total Spectrum is part of the LEARN Behavioral family of companies, a national organization dedicated to helping all children succeed in school and life. Learn more at https://www.learnbehavioral.com/

Share article on social media or email:

Medical Device Cybersecurity Assessment and Penetration Testing Services Now Offered Onsite at Alpine Security’s O’Fallon, Illinois Facility


There are 10-15 medical devices per hospital bed. Many of these are vulnerable to cyberattacks.

There are 10-15 medical devices per hospital bed. Many of these are vulnerable to cyberattacks.

“Innovative medical devices are used to diagnose patients and assist with patient surgery. It is vital we protect these critical medical devices from cybercriminals. It truly is a matter of life and death, where the impact of a cyberattack is very tangible.” – Christian Espinosa, Alpine Security CEO

Alpine Security has provided medical device cybersecurity assessment and testing service since 2016 and has continued to refine their medical device assessment and penetration testing capabilities. Prior to COVID-19, Alpine Security’s cybersecurity engineers traveled onsite to medical device manufacturing facilities to provide testing onsite, at client facilities. Due to safety and travel limitations associated with COVID-19, Alpine Security has converted one of their training classrooms to a medical device testing facility. Clients now ship their medical devices to Alpine Security’s facility for cybersecurity assessment and testing.

Alpine Security medical device manufacturing clients are thrilled with this new approach because it provides an alternative for testing during COVID-19, saves on travel costs, and offers more flexibility with testing timelines.

Alpine Security’s medical device testing framework references the following standards:

  • The Open Source Security Testing Methodology Manual
  • U.S. NIST SP 800-115: Technical Guide to Information Security Testing and Assessment
  • FDA Premarket Notification 510(k)
  • FDA Content of Premarket Submissions for Management of Cybersecurity in Medical Devices (2018 Draft)
  • EU Medical Device Regulation (MDR)
  • UL 2900 set of standards (UL’s Cybersecurity Assurance Program)

Alpine Security’s medical device cybersecurity assessment an penetration testing services consists of the following high-level activities:

  • Assess risk pertaining to confidentiality, integrity and availability
  • Assess entry points to systems
  • Assess existing controls
  • Assess data flows
  • Assess use cases
  • Assess and assist with the Threat Tree development
  • Assess and assist with the Traceability Matrix
  • Assess and assist with standard operating procedures
  • Assess and assist with software architecture cybersecurity
  • Recommend revisions to or new cybersecurity controls
  • Recommend design changes to reduce risk
  • White box medical device penetration testing

For more information on Alpine Security’s medical device cybersecurity assessment and testing services, you can reach them here:

— Phone: 844-925-7463

— Email: info@alpinesecurity.com

— Website: https://alpinesecurity.com/

ABOUT ALPINE SECURITY

Alpine Security focuses on several main areas to help prevent cybercrime:

  • Medical device cybersecurity – we work with medical device manufacturers to ensure their devices are secure from cyberattacks; that the medical device used by your healthcare provider on you or your loved one for diagnostics or surgery is safe and secure.
  • Fractional and virtual Chief Information Security Officer (CISO) – we work with SMBs to help assess cybersecurity risk and develop a cybersecurity roadmap. SMBs are vital to our economy. We want to do our part to help prevent data breaches.
  • Cybersecurity training – we work with individuals and organizations to increase cybersecurity skills, knowledge, and abilities. Increased awareness helps prevent cybercrime.

Share article on social media or email:

Mount Sinai Researchers Discover Treatment Option for Rare Genetic Disorder


Researchers from the Icahn School of Medicine used a novel genetic sequencing technology to identify the genetic cause of—and a treatment for—a previously unknown severe auto inflam-matory syndrome affecting an 18-year-old girl since infancy.

The technology, tailored to the patient’s own genetic code at a single cell level, helped the re-searchers characterize an unknown mutation in a gene called JAK1 that caused the patient’s immune system to be permanently turned on, resulting in rashes over much of her skin, growth abnormalities, kidney failure, allergic hypersensitivities, and an unusual inflammatory condi-tion throughout the digestive tract.

The study, led by Dusan Bogunovic, PhD, Associate Professor of Microbiology, and Pediatrics, at the Icahn School of Medicine at Mount Sinai, faculty member of The Mindich Child Health and Development Institute and the Precision Immunology Institute at Mount Sinai, and Director of the Center for Inborn Errors of Immunity, was published in the August 3 issue of the journal Immunity. The discovery points toward new ways to study how genetic diseases manifest and presents a model of personalized diagnosis and treatment for patients with genetic diseases.

Autoinflammatory diseases are caused by abnormal activation of the immune system, leading to recurrent episodes of inflammation that may result in damaged or failed organs. The researchers determined that not all of the patient’s cells carried this mutation and had different genetic makeups or genotypes, what the researcher describe as a mosaic.

“Most genes use both their maternal and paternal copies, called alleles,” said Dr. Bogunovic. “Our findings show the JAK1 mutation in this patient used only one copy per cell, known as monoallelic expression. This challenges the textbook principles of genetics and may help ex-plain irregularities that are frequently encountered across genetic diseases.”

In the paper, the researchers describe the use of next-generation genomic, molecular, and multi-parametric immunological tools to probe the effects of the patient’s JAK1 mutation. By map-ping the genotype of JAK1 across the patient’s body, researchers were able to pinpoint precisely when the mutation arose in early development in the embryo. It later gave way to a host of symptoms from early childhood to early adulthood. The hunt began for a specific therapy that would curb the excessive activity of her mutant JAK1 and potentially cure her inflammatory symptoms.

“We identified one drug, tofacitinib, a JAK inhibitor, that curbed the excessive activity of her hyperactive inflammation. When administered the therapy, she rapidly improved within weeks. Her skin lesions cleared, her daily gastrointestinal symptoms resolved, and the clinical signs of inflammation went away, putting the patient in remission for two years until her unfortunate demise from coronavirus-related illness,” said Dr. Bogunovic. “This research helps better un-derstand the basic function of JAK1, which has broad implications for diseases of the immune system and how to treat them. In addition, the genetic discoveries uncovered in this case open up new research avenues into the complexities of how genetic diseases manifest and present a model of the future of personalized medicine. By coupling advanced clinical care with next-generation sequencing and detailed laboratory studies, we successfully diagnosed and treated a life-threatening disease.”

The research was accomplished with collaboration from the Vagelos College of Physicians and Surgeons at Columbia University Irving Medical Center, The Rockefeller University and New York University Grossman School of Medicine in New York City and the Universite de Nantes and Centre Hospitalier Universitaire de Nantes in Nantes, France.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encom-passing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most se-rious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in the country. Mount Sinai Health Sys-tem hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twit-ter and YouTube.

Share article on social media or email:

DrBurns’ ReLeaf™ Products Honored With Prestigious Industry Awards


Physician formulated DrBurns’ ReLeaf™ products continue to win praise in the Cannabinoid marketplace for quality and efficacy. The company’s Muscle & Joint Ointment placed third in the 710 Degree Cup industry awards topical category. The CBD Pure Pain Tincture and the CBD Soothing Honey-Lemon Lozenge scored top honors from CBD Informative, an independent reviewing agency.

The products were developed by Dr. Elaine Burns, the first Arizona healthcare professional to pass the American Academy of Cannabinoid Medicine certification test. Top orthopedic and sports doctors regularly refer patients to Dr. Burns, as does Barrow Neurologic Institute and Banner Health. All DrBurns’ ReLeaf™ products are made from proprietary formulas with every batch’s potency verified through independent lab testing.

Dr. Burns ReLeaf™ Muscle & Joint Ointment is a THC infused powerhouse for pain management. It relieves pain through a proprietary 1:1 blend of 400 mg. of CBD and 400 mg. of THC along with other botanicals like arnica and willow to further its pain relief effectiveness. The product’s base is highly absorbable, and there is no smell of cannabis advertising that the wearer is using a medical marijuana product. DrBurns’ ReLeaf™ Muscle & Joint Ointment is available for qualifying patients at select Arizona licensed medical marijuana dispensaries.

DrBurns’ ReLeaf™ CBD Pure Pain Tincture was awarded a 9.8 out of a possible 10 points by CBD Informative, with a 99.5% accuracy rating. Previously, this same product was ranked third in the tincture category at the 710 Degree Cup.

The CBD Soothing Lozenges were awarded 8.63 points. Designed to help ease the symptoms of stress, depression and anxiety, DrBurns’ ReLeaf™ lozenges can be used daily for general wellness.

The CBD Pure Pain Tincture and CBD Soothing Lozenges do not contain THC and are available without a qualifying condition or prescription online.

CBD Informative provides third party testing, rating every product on potency, effects, taste and packaging. The categories are weighted, with a significant value placed on potency, which is verified through independent lab testing. Products lose points when this testing does not back up their stated potency.

For more information visit DrBurnsReLeaf.com.

Share article on social media or email:

Phrase Health Awarded NIH Grant To Align Electronic Health Record Data With Quality Outcomes


This is clearly a time saver. In one hour, you can accomplish what may take hours… congratulations, you really have streamlined an intimidating and terrible process.

Phrase Health, Inc, a Philadelphia-based healthcare technology company, was awarded a $224,995 Phase 1 Small Business Technology Transfer (STTR) grant from the National Library of Medicine (NLM), an institute within the National Institutes of Health (NIH). The funded proposal aims to facilitate care improvement and safety initiatives within the healthcare setting through the aggregation of quality measures and electronic health record (EHR) system data. As part of the research exploration, the Phrase Health team of clinicians, designers, and engineers are working closely with clinical informaticists and human factors experts at multiple academic health systems.

Health system quality improvement (QI) teams are often siloed from the informatics and information technology groups. “Informatics and quality leaders around the country frequently tell us that the EHR is integral to clinical workflows. However, aligning the EHR with important quality improvement initiatives remains extraordinarily difficult,” says Dr. Marc Tobias, Phrase Health’s CEO and a physician board certified in Clinical Informatics and Emergency Medicine.

The proposed research entails an iterative design process with user testing and evaluation. Early user research has yielded promising results. Participants unfamiliar with QI felt this product could empower them to quickly drive practice improvement. When walking through an onboarding prototype, one physician user remarked, “This is clearly a time saver. In one hour, you can accomplish what may take hours… congratulations, you really have streamlined an intimidating and terrible process.” Another physician trainee valued the reassuring guidance as she set up an initiative, saying “It feels more approachable – I might be able to identify a problem but I wouldn’t know the next steps. It makes it easier to start.”

In addition to development of the product, researchers at the participating institutions have sought to publicly disseminate their findings. Preliminary results, entitled “User and Task Analysis for Evaluation of Clinical Decision Support for Quality Improvement” were accepted in the peer-reviewed Proceedings of the Human Factors and Ergonomics Society (HFES) Annual Meeting. Furthermore, the project leads will present their work later this Fall at the HFES Annual Meeting and will participate in clinical decision support (CDS) focused presentations at the American Medical Informatics Association (AMIA) Annual Symposium.

In the meantime, the Phrase Health team plans on continued iteration of their product over the next year. Dr. Tobias states, “We are thrilled to have this grant support from the NIH and NLM. Their support through this grant represents the recognition of a significant problem that has stymied quality improvement. I’m excited to see the progress we’re making every day.”

About Phrase Health

Phrase Health is a healthcare technology company focused on improving the quality of clinical care delivery through the optimization and management of electronic health record data. The award-winning company, founded in 2018 within the Children’s Hospital of Philadelphia by several board certified clinical informatics physicians, provides web-based analytics dashboards to better understand clinical processes and electronic interventions like alerts and order sets. The company has customers that span academic health systems, community health networks, and stand-alone pediatric hospitals. Learn more at https://www.phrasehealth.com

Early findings reported in this press release were supported by the National Library of Medicine of the National Institutes of Health under award number R41LM013317. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Share article on social media or email:

Future Pharm Announces the Release of HEMPLETS™


HEMPLETS™

HEMPLETS™

We are excited to announce our patent pending Liposomal chewable tablet Hemplets! Science backed technology.

Future Pharm recently released its latest product, HEMPLETS™. HEMPLETS™ is the only liposomal chewable tablet in the world that has a patent pending liposome platform. It is designed to have an average particle distribution of 165 Nano meters, increases oral absorbance and bioavailability. HEMPLETS™ is designed to deliver a potent dose of CBD that is THC free in an oral tablet form unlike anything else. HEMPLETS™ is a highly advanced technology in a solid convenient chewable dosage form.

A liposome is a protective lipid layer that encapsulates CBD molecules by using liposomals as carriers. This led to the development of a completely new range of a CBD product that is patent pending. HEMPLETS™ liposomal CBD delivers products in chewable flavors that are unmatched in quality and scientifically proven while providing a fast and effective form of CBD supplementation. “We are excited to announce our patent pending Liposomal chewable tablet HEMPLETS™, which is science backed technology,” states Gina Haynie, founder of Future Pharm.

CBD is supplied in the USA by cGMP, FDA registered manufacturers using CO2 extraction. The solvent is considered a cleaner, purer form of extraction because there is no residue after extraction, which is what makes this new product so unique. HEMPLETS™ Liposome Chewable Tablets uses all-natural flavors and ingredients.

HEMPLETS™ is currently available for sale on the Future Pharm website and select retailers.

About Future Pharm

Future Pharm offers products developed to be used as a preventative and alternative solution for people seeking a natural option to health concerns, using plant-based remedies to help people heal their bodies and their lives. See the FAQ section of their website for list of ingredients in their products.

For more information, contact:

Gina Haynie, Founder

Future Pharm

info(at)myfuturepharm.com

https://myfuturepharm.com

T: (888) 841-7216

Share article on social media or email:

SACRIX, LLC Announces Successful Adoption of Its Revolutionary Bloodless Sacroiliac Fixation Technology At World Leading Academic Center In The USA


“This threaded device provides compressive stability so there is immediate pain relief” said SacroFuse inventor Professor Dr Kingsley R Chin

Sacrix, LLC, a KICVentures Company, invented a new 100% percutaneous posterior sacroiliac joint (SIJ) fixation technique that can be done in less than 20 minutes through a 1.5cm incision in an outpatient setting with no blood loss.

This new technique for outpatient SIJ fusion uses a pair of patented FDA-cleared threaded cannulated devices that can be placed over a guide wire easily and safely for joint compression that allows for the patient to go home the same day of surgery.

This was the first Sacrix procedure done at this world-leading academic center in the USA as a test case. After the surgery, the neurosurgeon remarked, “Sacrix is the best system for SIJ fusion I have used, it is simple, very easy to use, and straightforward.”

Sacrix has a patented device called SacroFuse which has varying thread configurations to create SIJ compression, a uniquely designed tip that allows for self-drilling and tapping, a threaded inserter that is secured to the implant for insertion and recovery, and a hollow caged cavity that auto-fills with bone graft as the device is inserted. SacroFuse can also be pre-packed and post-packed with flowable NanoFUSE Biologics.

“This threaded device provides compressive stability so there is immediate pain relief” said SacroFuse inventor Professor Dr Kingsley R Chin.

To schedule a Sacrix training and to learn more about this revolutionary technique contact Training@KICVentures.com and visit http://www.KICventures.com to learn more about other outpatient Less Exposure Surgery technologies for the least invasive outpatient spine surgery.

About Sacrix

Sacrix is a safe direct percutaneous outpatient procedure allowing for faster recovery and same day treatment. The posterior approach is indicated for the for the treatment of sacroiliitis and sacroiliac joint disruption. This allows for direct compression and fusion of the sacroiliac joint. The Sacrix SIJ treatment is a least invasive outpatient treatment option. Sacrix is a KICVentures portfolio company

About KICVentures

KICVentures is a private investment holding company founded by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed and NanoFUSE Biologics. It has headquarters in Boston, MA

Share article on social media or email:

The Illinois Primary Health Care Association Partners with Luma Health to Streamline Access to Care Throughout the State of Illinois


Patient engagement solutions for FQHC, Community Health Centers

IPHCA selects Luma Health to support Illinois’ 51 Federally Qualified Health Centers (FQHCs) with cutting-edge technology to boost access to care and implement patient engagement best practices.

“We wanted a multilingual solution that could support health centers’ efforts to increase access to care and fill care gaps, while also driving down no-show rates and supporting chronic disease self-management. The Luma Health platform addresses these needs,” said Jordan Powell, CEO of the IPHCA.

Luma Health, the leader in total patient engagement, today announced that it has been selected as a strategic Primary Health Purchasing Alliance partner by the The Illinois Primary Health Care Association (IPHCA) to modernize and accelerate access to care for more than 1.4M patients and countless communities across Illinois. The partnership between Luma Health and IPHCA will empower Illinois’ 51 Federally Qualified Health Centers (FQHCs) with cutting-edge technology to boost access to care and implement patient engagement best practices, ultimately strengthening the health of Illinois’ communities.

“The IPHCA is tasked with finding solutions to help with clinical pain points among our member health centers,” said Jordan Powell, CEO of the IPHCA. “Specifically, we wanted a multilingual solution that could support health centers’ efforts to increase access to care and fill care gaps while also driving down no-show rates and supporting chronic disease self-management. The capabilities of the Luma Health platform address these needs.”

FQHCs are committed to providing comprehensive primary and preventive healthcare services to all through a patient-centered approach, and to making that care accessible and impactful to a diverse patient population through additional support services ranging from health education to transportation.

Using mobile-first patient engagement technology, the Luma Health platform supports this patient-centered approach by facilitating consistent communication between health centers and the populations they serve with personalized communication throughout the entire patient lifecycle.

With Luma Health, health centers can streamline outreach efforts, patients can self-schedule appointments, providers can reduce no-shows and optimize their schedules through smart reminders and waitlists, and health centers can reach outside the four walls of their clinics to better deliver patient-specific health education content in 20-plus languages. Together, health centers and Luma Health will drive improved communication between patients and providers during — and outside of — traditional office visits, speeding access to care for more patients and helping providers deliver a better experience and improved outcomes.

“Health centers and Luma Health together have a proven record of success in moving the needle on community health. By leveraging the Luma Health platform, one health center was able to more than triple its outreach conversion rate, which translates to getting more patients the care they need,” said Adnan Iqbal, CEO and co-founder of Luma Health. “Using our technology, that same health center increased access to preventive screenings by more than 30%. We are proud and excited to partner with IPHCA to drive an even greater impact for Illinois’ communities.”

To learn more about the Luma Health platform, visit http://www.lumahealth.io/platform. For more information on the partnership between Luma Health and IPHCA, visit https://www.iphca.org/group-purchasing/.

About the Illinois Primary Health Care Association

IPHCA is a health care trade association representing Illinois’ 51 community health centers that collectively serve more than 1.4 million patients at 390 sites statewide. Community health centers provide accessible, comprehensive and integrated services and are known for providing high quality outcomes while substantially reducing health care expenditures, saving the state of Illinois nearly $2 billion on an annual basis according to an independent economic analysis. Learn more about IPHCA at http://www.iphca.org.

About Luma Health

Luma Health’s mission is to empower leading healthcare providers to deliver personalized and engaging experiences across the entire patient journey. Its Patient Engagement Platform enables health providers to manage the patient journey and optimize every interaction to maximize patient outcomes, boost top-line revenue growth, reduce total cost of care, and boost patient retention.

Headquartered in San Francisco, CA, Luma Health’s platform is modernizing communication by delivering smarter conversations that drive patient engagement and continuous care, with over 160,000 providers and over 6 million patients across the US today. Additional information about the company is available at http://www.lumahealth.io, Luma Health Blog, LinkedIn, Facebook, @lumahealthhq.

Share article on social media or email:

Cloudticity Named to Fast Company’s First-Ever List of the Most Innovative Teams of the Year


The organizations on the Best Workplaces for Innovators list have created cultures that empower employees at all levels to thrive.

Fast Company recently announced the winners of Innovative Team of the Year, a new category within its annual Best Workplaces for Innovators list, which highlights the most innovative teams—groups of employees, nominated by their companies, that took advantage of a pro-innovation environment to build or develop something extraordinary. Cloudticity was recognized as an honorable mention on the list.

The team of the year was the Pandemic Response Team at biotech firm AbCellera, which combined microfluidics, data science, machine learning, bioinformatics, and genomics to bring the first COVID-19 antibody to clinical trials in under 90 days, a process that typically requires three to six years.

“The organizations on the Best Workplaces for Innovators list have created cultures that empower employees at all levels to thrive. This year, we wanted to recognize the people and teams that embraced the challenge to innovate by allowing employers to nominate internal working groups for Innovative Team of the Year,” said Fast Company editor-in-chief Stephanie Mehta.

Developed in collaboration with Accenture, the 2020 Best Workplaces for Innovators list showcases 100 winners from a variety of industries, including computer science, biotech, consumer-packaged goods, financial services, cybersecurity, and engineering.

“At Cloudticity we value our ability to provide a safe space for employees to be creative, to experiment, to make mistakes, and to try again. By giving the team permission to fail we’ve found that they’re able to achieve successes that surpass what was initially envisioned. We are thankful to Fast Company for recognizing that Cloudticity is a great workplace for innovators,” said Gerry Miller, Founder and CEO at Cloudticity.

Cloudticity is a cloud technology partner that focuses exclusively on helping healthcare organizations be successful on the public cloud. Distinguished for having built some of the largest healthcare systems on the cloud, including the first patient portal, the first health information exchange, and the first meaningful use compliance for a large hospital system, Cloudticity solutions empower healthcare organizations to deliver the next generation of lifesaving healthcare solutions.

Most recently Cloudticity has been recognized by Amazon Web Services (AWS) for Best Solution Delivering COVID-19 Value in the AWS Public Sector Partners Awards 2020. You can learn more about Cloudticity’s award winning implementation in the state of New York here.

To see the complete list, go to: http://www.fastcompany.com/best-workplaces-for-innovators/2020

Fast Company’s Best Workplaces for Innovators issue (September 2020) is available online now, and the print issue will be on newsstands beginning August 11, 2020. Join the Best Workplaces for Innovators conversation, using #FCBestWorkplaces.

ABOUT FAST COMPANY

Fast Company is one of the world’s leading business media brands, with an editorial focus on innovation and deep emphasis on creativity, technology, social impact, leadership, and design. Headquartered in New York City, Fast Company magazine is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

ABOUT ACCENTURE

Accenture is a leading global professional-services company, providing a broad range of services and solutions in strategy, consulting, digital, technology, and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions—underpinned by the world’s largest delivery network—Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With 482,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at accenture.com.

ABOUT CLOUDTICITY

Cloudticity helps healthcare organizations transform healthcare by unlocking the full potential of the cloud. Through groundbreaking automation and deep cloud and healthcare expertise, Cloudticity solutions empower healthcare organizations to develop, deploy, and scale the industry’s next breakthrough solutions. Unleash healthcare ingenuity without limits. Learn more at cloudticity.com

For more information contact:

Kate Z. Wang

Director of Marketing

Cloudticity

kate.wang@cloudticity.com

Share article on social media or email: